In this study, ER+ breast cancer cells with ARID1A loss showed increased tumor growth in both untreated and 4-hydroxytamoxifen (a selective estrogen receptor modulator)-treated cells compared to ARID1A wild-type. Here, ARID1A is linked to breast carcinoma.